3.Psoriatic Arthritis That Responded Dramatically When Infliximab Was Switched to Adalimumab.
Yuichiro OHSHIMA ; Yumi KINOSHITA ; Yoichi AKITA ; Yasuhiko TAMADA ; Daisuke WATANABE
Annals of Dermatology 2013;25(4):496-497
No abstract available.
Antibodies, Monoclonal
;
Antibodies, Monoclonal, Humanized
;
Arthritis, Psoriatic*
;
Adalimumab
;
Infliximab
4.Bevacizumab and oral metronomic cyclophosphamide in platinum-resistant ovarian cancer.
Journal of Gynecologic Oncology 2013;24(3):209-211
No abstract available.
Antibodies, Monoclonal, Humanized
;
Bevacizumab
;
Cyclophosphamide
;
Ovarian Neoplasms
5.Cetuximab Related Eyelash Elongations for Patients with Metastatic Rectum Carcinoma: Metabolic Complete Response.
Annals of Dermatology 2013;25(4):504-505
No abstract available.
Antibodies, Monoclonal, Humanized
;
Humans
;
Rectum*
;
Cetuximab
7.A Long Term Case Series Study of the Effect of Omalizumab on Chronic Spontaneous Urticaria.
Anna Cecilie LEFEVRE ; Mette DELEURAN ; Christian VESTERGAARD
Annals of Dermatology 2013;25(2):242-245
No abstract available.
Antibodies, Anti-Idiotypic
;
Antibodies, Monoclonal, Humanized
;
Urticaria
;
Omalizumab
8.Clinical Results After Application of Bevacizumab in Recurrent Pterygium.
Jong Wook LEE ; Young Jeung PARK ; In Taek KIM ; Kyoo Won LEE
Journal of the Korean Ophthalmological Society 2008;49(12):1901-1909
PURPOSE: To clinically establish the effectiveness and safety of bevacizumab on recurrent pterygium. METHODS: Twenty patients with recurrent pterygium were given a subconjunctival injection of 0.3 cc bevacizumab, and were evaluated for periodic clinical results at 1 week, 2 weeks, 4 weeks, and every month thereafter. The patients were also evaluated for clinical results and complications. RESULTS: Of recurrent pterygium patients with bevacizumab injection, the conjunctival injection decreased maximally after 1 to 2 weeks, but significantly increased at 4 weeks (above the lowest level measured at 1 to 2 weeks), and no patient presented conjunctival injection above the pre-injection level at 3 months, except in 2 cases. Two weeks after the injection, ICG anterior segment angiography revealed a significant decrease (30.14+17.69%) in vessel thickness of the pterygium 2 weeks after the bevacizumab injection compared to before the injection. There had been no cases of progression of pterygium, and no ocular or systemic complications due to bevacizumab. CONCLUSIONS: As shown above in the results, subconjunctival injection of 0.3 cc bevacizumab decreased the conjunctival injection and effectively suppressed any further progression of pterygium. Thus, bevacizumab subconjunctival injection appears to be effective in recurrent pterygium treatment instead of surgical methods.
Angiography
;
Antibodies, Monoclonal, Humanized
;
Glycosaminoglycans
;
Humans
;
Pterygium
;
Bevacizumab
9.The Efficacy of Vedolizumab, an alpha4beta7 Integrin Antibody, in Crohn's Disease and Ulcerative Colitis.
Intestinal Research 2013;11(4):325-326
No abstract available.
Antibodies, Monoclonal, Humanized
;
Colitis, Ulcerative*
;
Crohn Disease*
;
Ulcer*
10.Asthma Year in Review.
Tuberculosis and Respiratory Diseases 2010;69(6):411-417
This review highlights articles pertaining to the following 5 topics: the relationship between asthma, allergic and non-allergic rhinitis; the novel asthma phenotypes using cluster analysis; the diagnostic properties of inhaled dry-powder mannitol for the diagnosis of asthma; the value of mepolizumab therapy in exacerbations of refractory eosinophilic asthma; the role of bronchial thermoplasty in the treatment of severe asthma.
Antibodies, Monoclonal, Humanized
;
Asthma
;
Cluster Analysis
;
Eosinophils
;
Mannitol
;
Phenotype
;
Rhinitis